Coherus Biosciences Inc (NASDAQ:CHRS) insider Barbara K. Finck sold 1,760 shares of the firm’s stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $19.02, for a total transaction of $33,475.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Barbara K. Finck also recently made the following trade(s):

  • On Monday, June 18th, Barbara K. Finck sold 1,760 shares of Coherus Biosciences stock. The stock was sold at an average price of $15.00, for a total transaction of $26,400.00.

Coherus Biosciences stock traded down $0.10 during midday trading on Friday, hitting $18.65. 4,340 shares of the stock were exchanged, compared to its average volume of 722,697. Coherus Biosciences Inc has a fifty-two week low of $8.05 and a fifty-two week high of $19.60. The stock has a market cap of $1.29 billion, a P/E ratio of -4.17 and a beta of 3.68. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 1.66.

Coherus Biosciences (NASDAQ:CHRS) last released its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.04). analysts forecast that Coherus Biosciences Inc will post -3.05 EPS for the current year.

Several research firms recently issued reports on CHRS. Zacks Investment Research cut shares of Coherus Biosciences from a “hold” rating to a “sell” rating in a research report on Monday. ValuEngine upgraded shares of Coherus Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 2nd. BidaskClub cut shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a research report on Saturday, June 16th. Finally, Maxim Group raised their price objective on shares of Coherus Biosciences from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, May 11th. One analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Coherus Biosciences presently has a consensus rating of “Buy” and a consensus price target of $25.20.

A number of institutional investors have recently added to or reduced their stakes in CHRS. Brown Advisory Inc. increased its stake in shares of Coherus Biosciences by 0.8% during the 1st quarter. Brown Advisory Inc. now owns 637,977 shares of the biotechnology company’s stock valued at $7,049,000 after acquiring an additional 4,942 shares during the last quarter. Swiss National Bank increased its position in Coherus Biosciences by 7.6% during the 2nd quarter. Swiss National Bank now owns 70,500 shares of the biotechnology company’s stock worth $987,000 after purchasing an additional 5,000 shares in the last quarter. Wells Fargo & Company MN increased its position in Coherus Biosciences by 2.7% during the 1st quarter. Wells Fargo & Company MN now owns 218,448 shares of the biotechnology company’s stock worth $2,413,000 after purchasing an additional 5,658 shares in the last quarter. Royal Bank of Canada increased its position in Coherus Biosciences by 26.2% during the 1st quarter. Royal Bank of Canada now owns 32,526 shares of the biotechnology company’s stock worth $360,000 after purchasing an additional 6,754 shares in the last quarter. Finally, Tower Research Capital LLC TRC acquired a new stake in Coherus Biosciences during the 2nd quarter worth approximately $118,000. Hedge funds and other institutional investors own 90.30% of the company’s stock.

About Coherus Biosciences

Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.

Read More: Market Capitalization and Individual Investors

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.